**International Journal of Pharmacy and Pharmaceutical Research (IJPPR)**
Volume 32, Issue 4, April 2026 **ijppr.humanjournals.com** ISSN: 2349-7203

# Harnessing Polyherbal Synergy for Pain and Inflammation: Mechanistic and In Vivo Insights from Turmeric, Ginger, and Boswellia

**Ishteha Hussain; Utkarsh Sharma; Anurag Singh**

Advance Institute of Biotech and Paramedical Sciences, Kanpur, India.

Received: 28 February 2026 Revised: 15 March 2026 Accepted: 31 March 2026

**ABSTRACT**

Inflammation is a complex biological response that plays a central role in the pathogenesis of numerous acute and chronic disorders, including arthritis, metabolic diseases, and autoimmune conditions. Although conventional anti-inflammatory therapies, particularly non-steroidal anti-inflammatory drugs (NSAIDs), are widely utilized for the management of inflammatory conditions, their prolonged use is frequently associated with significant adverse effects such as gastrointestinal irritation, renal dysfunction, and cardiovascular complications. These limitations have stimulated growing interest in plant-derived therapeutic strategies capable of modulating multiple inflammatory pathways while offering improved safety profiles. In this context, polyherbal formulations have gained considerable attention, as the combination of multiple medicinal plants may enhance therapeutic efficacy through synergistic phytochemical interactions.This review comprehensively examines the mechanistic basis and in vivo pharmacological evidence supporting a polyherbal anti-inflammatory and analgesic formulation composed of Curcuma longa, Zingiber officinale, and boswellic acid–rich extracts derived from Boswellia serrata. These medicinal plants are rich sources of diverse bioactive phytoconstituents, including curcuminoids, gingerols, shogaols, and pentacyclic triterpenoid boswellic acids, which exhibit potent anti-inflammatory and analgesic properties through complementary molecular mechanisms. Experimental evidence indicates that these phytochemicals modulate key inflammatory signaling pathways by inhibiting cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzymes, suppressing nuclear factor-κB (NF-κB) activation, and attenuating the production of pro-inflammatory mediators such as tumor necrosis factor-α (TNF-α), interleukin-1β, and interleukin-6. Furthermore, in vivo studies employing established experimental models—including carrageenan-induced paw edema and cotton pellet granuloma assays—have demonstrated significant reductions in inflammatory responses following administration of these herbal extracts and their combinations. Collectively, the available pharmacological evidence highlights the potential of the turmeric–ginger–boswellia polyherbal system as a promising multi-target therapeutic strategy for the management of inflammatory disorders and associated pain conditions.

**Keywords :** Polyherbal formulation; Anti-inflammatory activity; Analgesic activity; Phytochemical synergy; Curcumin; Boswellic acids; Gingerols

## 1. INTRODUCTION

### 1.1 Global Burden of Inflammatory Disorders and Pain

Inflammation is a complex physiological response triggered by infection, tissue injury, or immune dysregulation and represents a fundamental defense mechanism aimed at restoring tissue homeostasis. However, persistent or dysregulated inflammatory responses are strongly implicated in the pathogenesis of numerous chronic diseases, including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, metabolic disorders, cardiovascular diseases, and neurodegenerative conditions [1-4]. Chronic low-grade inflammation has increasingly been recognized as a key pathogenic factor underlying many non-communicable diseases worldwide [2,5]. Epidemiological evidence indicates that approximately three out of five global deaths are associated with chronic inflammatory conditions such as cardiovascular disease, diabetes, cancer, and chronic respiratory disorders [6].

Musculoskeletal inflammatory disorders represent a major contributor to global disability and healthcare burden. Rheumatoid arthritis affects millions of individuals worldwide and remains one of the leading causes of functional disability and reduced quality of life [7,8]. Global epidemiological studies estimate that more than 17 million individuals are affected by rheumatoid arthritis worldwide [8]. Furthermore, osteoarthritis is another prevalent inflammatory joint disorder affecting hundreds of millions of individuals globally and representing a major cause of disability and impaired mobility [9].

In addition to joint disorders, inflammatory bowel disease and other immune-mediated inflammatory diseases are increasingly prevalent worldwide [10]. Global epidemiological studies have reported millions of cases of inflammatory bowel disease with increasing incidence particularly in industrialized and developing regions [11]. Collectively, these conditions impose a substantial socioeconomic burden due to chronic morbidity, healthcare expenditures, and productivity loss. Therefore, identifying effective and safe therapeutic strategies for the management of inflammation and associated pain remains a major priority in biomedical research.

### 1.2 Limitations of Conventional Anti-Inflammatory and Analgesic Therapies

Conventional pharmacological management of inflammation and pain primarily relies on non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and opioid analgesics [12]. NSAIDs exert their therapeutic effects mainly through inhibition of cyclooxygenase (COX) enzymes responsible for prostaglandin synthesis, thereby reducing inflammation, fever, and pain [13]. While these agents are highly effective for symptomatic relief, their prolonged use is frequently associated with significant adverse effects, including gastrointestinal ulceration, bleeding, renal impairment, and cardiovascular complications [14,15]. These limitations restrict their long-term clinical use, particularly in patients with chronic inflammatory diseases.

Similarly, corticosteroids are potent anti-inflammatory agents that suppress immune responses by inhibiting inflammatory gene transcription and cytokine production [16]. However, chronic corticosteroid therapy can result in serious side effects such as osteoporosis, metabolic disturbances, hypertension, and increased susceptibility to infections [17]. Opioid analgesics, although effective for severe pain management, carry risks of tolerance, dependence, and addiction, posing major public health concerns [18]. Consequently, there is a growing need for safer therapeutic alternatives capable of modulating inflammatory pathways without producing significant systemic toxicity.

### 1.3 Growing Interest in Plant-Derived Therapeutics

In recent decades, increasing scientific attention has been directed toward medicinal plants as potential sources of safer and more effective anti-inflammatory agents [19]. Plant-derived bioactive compounds possess diverse chemical structures and pharmacological activities, enabling them to modulate multiple molecular targets involved in inflammatory pathways [20]. Numerous phytochemicals, including polyphenols, flavonoids, terpenoids, and alkaloids, have demonstrated significant anti-inflammatory and antioxidant properties in experimental and clinical studies [21].

Among these phytochemicals, curcumin derived from Curcuma longa has been extensively investigated for its anti-inflammatory potential [22]. Curcumin has been shown to inhibit key inflammatory mediators such as nuclear factor-κB (NF-κB), cyclooxygenase-2 (COX-2), and lipoxygenase (LOX), thereby reducing the production of pro-inflammatory cytokines including tumor necrosis factor-α and interleukins [23].

Similarly, Zingiber officinale contains bioactive constituents such as gingerols and shogaols that exhibit potent anti-inflammatory and antioxidant activities [24]. These compounds have been reported to suppress NF-κB activation, reduce oxidative stress, and inhibit COX-mediated inflammatory pathways [25].

Another well-known medicinal plant, Boswellia serrata, produces pentacyclic triterpenoid compounds known as boswellic acids, which have demonstrated significant anti-inflammatory effects primarily through inhibition of 5-lipoxygenase and leukotriene synthesis [26-28].

### 1.4 Scientific Rationale for Polyherbal Formulations

While individual medicinal plants possess notable pharmacological activities, the concept of polyherbal formulations has gained considerable attention in modern phytopharmaceutical research [29]. Polyherbal formulations involve the combination of two or more medicinal plants in a single therapeutic preparation to achieve enhanced efficacy through synergistic interactions among their phytochemical constituents [30].

The scientific rationale behind polyherbal therapy lies in the principle of multi-target pharmacology. Unlike single-compound drugs that typically act on a specific molecular target, polyherbal formulations contain multiple bioactive constituents capable of simultaneously modulating different biochemical pathways involved in disease progression [31]. For inflammatory disorders, this multi-target approach may include inhibition of COX and LOX pathways, suppression of NF-κB signaling, modulation of pro-inflammatory cytokines, and attenuation of oxidative stress [32,33].

### 1.5 Scope and Objectives of the Review

Given the increasing global burden of inflammatory diseases and the limitations of existing pharmacological therapies, there is a growing need to explore alternative therapeutic strategies based on evidence-based herbal medicine [34]. In this context, polyherbal formulations composed of turmeric, ginger, and boswellia have attracted significant research interest due to their well-documented anti-inflammatory and analgesic properties [35-37].

The primary objective of this review is to critically evaluate the mechanistic basis and pharmacological evidence supporting the anti-inflammatory and analgesic potential of a polyherbal formulation containing turmeric, ginger, and boswellia. Specifically, this review aims to examine the molecular pathways involved in inflammation and pain, analyze the phytochemical composition and pharmacological activities of these medicinal plants, explore the concept of synergistic phytochemical interactions in polyherbal systems, and summarize the available in vivo experimental evidence supporting their therapeutic potential [38-40].

## 2. Molecular Basis of Inflammation and Pain

### 2.1 Overview of Inflammatory Processes

Inflammation is a complex biological response of vascular tissues to harmful stimuli such as pathogens, damaged cells, toxic compounds, or irritants. It represents a protective mechanism aimed at eliminating the initial cause of cell injury and initiating tissue repair. The inflammatory process involves coordinated interactions among immune cells, endothelial cells, signaling molecules, and transcription factors that collectively regulate the host defense system. Inflammation is generally categorized into acute and chronic phases. Acute inflammation is characterized by rapid onset and is typically mediated by the activation of innate immune cells such as neutrophils and macrophages, whereas chronic inflammation involves prolonged immune activation that contributes to tissue damage and disease progression [41,42].

The initiation of inflammation occurs when pattern recognition receptors (PRRs), including toll-like receptors (TLRs), recognize pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). This recognition activates intracellular signaling cascades that stimulate the production of inflammatory mediators, chemokines, and cytokines. These mediators promote vascular permeability, leukocyte recruitment, and activation of immune responses at the site of injury or infection. Persistent activation of these inflammatory pathways can lead to chronic inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease, and cardiovascular disorders [43,44]. Recent research has highlighted the importance of interconnected signaling pathways, including NF-κB and MAPK cascades, in regulating inflammatory responses and maintaining immune homeostasis [45].

### 2.2 Key Inflammatory Mediators

Inflammatory responses are mediated by a wide range of biochemical molecules collectively referred to as inflammatory mediators. These include cytokines, chemokines, prostaglandins, leukotrienes, nitric oxide (NO), and reactive oxygen species (ROS). These mediators are produced primarily by activated macrophages, neutrophils, mast cells, and endothelial cells during immune responses. Among these molecules, prostaglandins and leukotrienes derived from arachidonic acid metabolism play central roles in the regulation of inflammatory reactions and pain signaling [46,47].

Cytokines represent another major group of inflammatory mediators involved in immune regulation. Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) are rapidly released during inflammatory responses and contribute to the amplification of immune signaling pathways. These cytokines stimulate the recruitment of immune cells, enhance vascular permeability, and activate transcription factors that regulate the expression of inflammatory genes. Conversely, anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β) help regulate inflammatory responses and prevent excessive tissue damage [48,49].

### 2.3 Role of Cytokines and Prostaglandins

Cytokines and prostaglandins are among the most important mediators involved in inflammatory signaling and immune regulation. Cytokines are small secreted proteins that act as signaling molecules between immune cells, orchestrating immune responses and inflammatory reactions. Pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 play critical roles in activating immune cells, inducing fever, and promoting the synthesis of other inflammatory mediators. These cytokines also stimulate intracellular signaling pathways that regulate gene expression associated with inflammation [50].

Prostaglandins are lipid mediators derived from arachidonic acid through the action of cyclooxygenase enzymes. Among them, prostaglandin $E_2$ ($PGE_2$) is one of the most important mediators involved in inflammatory responses and pain perception. Prostaglandins contribute to vasodilation, increased vascular permeability, and sensitization of nociceptors, thereby enhancing pain and inflammation. Furthermore, cytokines and prostaglandins often interact synergistically to amplify inflammatory responses, leading to sustained immune activation in chronic inflammatory diseases [51,52].

### 2.4 Major Inflammatory Signaling Pathways

Inflammatory responses are regulated by several intracellular signaling pathways that coordinate immune activation and inflammatory mediator production. Among these pathways, the cyclooxygenase (COX), lipoxygenase (LOX), nuclear factor-κB (NF-κB), and mitogen-activated protein kinase (MAPK) pathways are considered central regulators of inflammation.

#### Cyclooxygenase (COX) Pathway

The cyclooxygenase pathway plays a pivotal role in the synthesis of prostaglandins from arachidonic acid. Two major isoforms of cyclooxygenase enzymes have been identified: COX-1 and COX-2. COX-1 is constitutively expressed in most tissues and is responsible for maintaining physiological functions such as gastric mucosal protection and platelet aggregation. In contrast, COX-2 is an inducible enzyme that is upregulated during inflammatory responses and leads to increased production of prostaglandins, particularly $PGE_2$, which contributes to inflammation and pain [53,54]. Consequently, inhibition of COX-2 has become a primary therapeutic target for anti-inflammatory drugs.

#### Lipoxygenase (LOX) Pathway

The lipoxygenase pathway represents another important mechanism involved in inflammatory mediator production. LOX enzymes catalyze the oxidation of arachidonic acid to produce leukotrienes and hydroxyeicosatetraenoic acids (HETEs), which are potent inflammatory mediators. Leukotrienes contribute to leukocyte recruitment, vascular permeability, and bronchoconstriction during inflammatory responses. Dysregulation of the LOX pathway has been associated with several inflammatory diseases, including asthma, arthritis, and cardiovascular disorders [55,56].

#### NF-κB Signaling Pathway

The nuclear factor-κB (NF-κB) signaling pathway is widely recognized as a master regulator of inflammation. NF-κB is a transcription factor that controls the expression of numerous genes involved in immune and inflammatory responses. Under normal conditions, NF-κB remains inactive in the cytoplasm bound to inhibitory proteins known as IκBs. Upon stimulation by inflammatory signals such as cytokines, bacterial lipopolysaccharide (LPS), or oxidative stress, IκB proteins are phosphorylated and degraded, allowing NF-κB to translocate into the nucleus and activate transcription of inflammatory genes [57,58]. Activation of NF-κB results in the production of pro-inflammatory cytokines, chemokines, adhesion molecules, and enzymes such as COX-2 and inducible nitric oxide synthase (iNOS), thereby amplifying inflammatory responses [59].

#### MAPK Signaling Pathway

The mitogen-activated protein kinase (MAPK) pathway is another crucial signaling cascade involved in the regulation of inflammation. MAPK signaling consists of several kinase families, including extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK. These kinases are activated in response to inflammatory stimuli and regulate cellular processes such as gene expression, cell proliferation, and apoptosis. Activation of the MAPK pathway leads to increased production of inflammatory mediators and cytokines, contributing to the progression of inflammatory diseases. Importantly, MAPK signaling interacts with NF-κB and other transcription factors to coordinate the overall inflammatory response [60].

## 3. Polyherbal Therapeutics: Concept and Scientific Rationale

### 3.1 Definition and Principles of Polyherbal Formulations

Polyherbal formulations refer to therapeutic preparations composed of two or more medicinal plant extracts combined in a defined ratio to produce enhanced pharmacological effects. This concept is deeply rooted in traditional medical systems such as Ayurveda, Traditional Chinese Medicine (TCM), and Unani medicine, where herbal combinations have historically been used to enhance therapeutic efficacy and reduce toxicity. The principle underlying polyherbal therapy is that multiple bioactive constituents present in different plants can interact synergistically to influence several biological targets simultaneously, thereby improving overall therapeutic outcomes [61,62].

Modern phytopharmaceutical research has increasingly adopted this concept to develop evidence-based herbal medicines with improved efficacy and safety profiles. Polyherbal formulations are designed based on complementary pharmacological actions of individual plant constituents, enabling them to modulate various biochemical pathways involved in disease pathogenesis. Such formulations are often standardized using advanced analytical techniques to ensure consistent phytochemical composition and pharmacological activity [63]. Furthermore, recent advances in systems biology and network pharmacology have provided deeper insights into the complex interactions between phytochemicals and biological targets, supporting the scientific rationale for polyherbal therapeutics [64].

### 3.2 Advantages of Polyherbal Therapy over Single-Herb Therapy

Compared with single-herb preparations, polyherbal formulations offer several pharmacological and therapeutic advantages. One of the primary benefits is the potential for synergistic interactions among multiple phytochemicals, which can enhance therapeutic efficacy while minimizing adverse effects. In many cases, individual plant extracts may exhibit moderate biological activity, whereas their combination can produce significantly stronger pharmacological effects due to complementary mechanisms of action [65].

Another advantage of polyherbal therapy is its ability to target multiple pathological pathways simultaneously. Chronic inflammatory diseases often involve complex molecular mechanisms including oxidative stress, immune dysregulation, cytokine imbalance, and metabolic disturbances. Polyherbal formulations containing diverse phytoconstituents can modulate these pathways collectively, providing a more comprehensive therapeutic approach compared with single-target drugs [66].

Moreover, certain phytochemicals present in herbal combinations may enhance the bioavailability and stability of other active constituents. For example, some plant metabolites can improve intestinal absorption or reduce metabolic degradation of co-administered compounds, thereby enhancing their pharmacokinetic properties. These interactions contribute to improved therapeutic outcomes and support the use of polyherbal strategies in modern herbal medicine [67].

### 3.3 Multi-Target Pharmacology of Herbal Medicines

One of the most significant scientific concepts underlying polyherbal therapy is multi-target pharmacology. Unlike conventional drugs that typically act on a single molecular target, herbal medicines contain numerous bioactive constituents capable of interacting with multiple cellular pathways simultaneously. This property is particularly beneficial in the management of complex diseases such as inflammation, cancer, metabolic disorders, and neurodegenerative diseases, where multiple signaling pathways contribute to disease progression [68].

Recent advances in network pharmacology and computational biology have revealed that herbal compounds often interact with diverse molecular targets including enzymes, transcription factors, cytokines, and receptors. These interactions create a network of pharmacological effects that collectively regulate disease-related pathways. For example, phytochemicals may inhibit inflammatory enzymes, modulate transcription factors, regulate immune cell signaling, and neutralize oxidative stress simultaneously [69].

In the context of inflammatory diseases, this multi-target activity allows herbal medicines to modulate several key signaling pathways, including nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and cyclooxygenase (COX) pathways. Such simultaneous modulation of multiple pathways contributes to the overall anti-inflammatory and analgesic effects of polyherbal formulations [70].

### 3.4 Concept of Phytochemical Synergy

Phytochemical synergy refers to the phenomenon in which multiple plant-derived compounds interact in a manner that enhances their combined pharmacological activity beyond the effects of individual constituents. This concept is widely recognized as a fundamental principle underlying the therapeutic efficacy of polyherbal formulations. Synergistic interactions can occur through several mechanisms, including pharmacodynamic synergy, pharmacokinetic enhancement, and modulation of metabolic pathways [71].

Pharmacodynamic synergy occurs when different phytochemicals act on complementary biological targets, resulting in amplified therapeutic effects. For instance, one compound may inhibit inflammatory enzymes while another modulates cytokine signaling pathways, collectively producing stronger anti-inflammatory activity. Pharmacokinetic synergy, on the other hand, involves interactions that improve the absorption, distribution, metabolism, or elimination of active compounds, thereby enhancing their bioavailability and therapeutic effectiveness [72].

Recent studies employing metabolomics, proteomics, and network pharmacology approaches have provided strong evidence supporting the existence of phytochemical synergy in herbal formulations. These advanced analytical tools have revealed complex interactions among plant constituents and their biological targets, demonstrating how polyherbal combinations can exert enhanced pharmacological effects compared with isolated compounds. Understanding these synergistic interactions is essential for the rational design and development of standardized polyherbal formulations for therapeutic applications [73-75].

## 4. Phytochemical and Pharmacological Profile of Selected Medicinal Plants

**Table 1: Phytochemical and Pharmacological Profile of *Curcuma longa***

| Category | Key Information | Pharmacological Relevance | References |
|---|---|---|---|
| **Botanical characteristics** | *Curcuma longa* L. (Family: Zingiberaceae) is a perennial rhizomatous medicinal plant extensively cultivated in tropical regions of Asia. The yellow-orange rhizome represents the principal medicinal part and has long been utilized in traditional medical systems including Ayurveda and Traditional Chinese Medicine for inflammatory and metabolic disorders. | Traditional therapeutic use in inflammatory conditions, wound healing, digestive disorders, and arthritis. | 75,76 |
| **Major phytochemical constituents** | The rhizome contains a complex phytochemical profile dominated by curcuminoids (curcumin, demethoxycurcumin, bisdemethoxycurcumin) along with volatile oils including ar-turmerone, α-turmerone, β-turmerone, and zingiberene, as well as polysaccharides and phenolic compounds. | Curcumin represents the primary pharmacologically active constituent responsible for antioxidant, anti-inflammatory, and immunomodulatory activities. | 77,78 |
| **Anti-inflammatory molecular mechanisms** | Curcuminoids regulate multiple inflammatory signaling cascades involved in immune activation and inflammatory mediator production. | Inhibition of NF-κB transcriptional activation; suppression of COX-2 and 5-LOX enzymes; downregulation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6); modulation of MAPK signaling and oxidative stress pathways. | 79,80 |
| **Analgesic pharmacological activity** | Experimental studies demonstrate that turmeric extracts and curcumin exert significant analgesic effects in inflammatory and nociceptive pain models. | Reduction of prostaglandin synthesis, inhibition of inflammatory mediators, modulation of TRPV1 receptors, and attenuation of nociceptive responses in models such as carrageenan-induced paw edema and hot-plate assays. | |

**Table 2: Phytochemical and Pharmacological Profile of *Zingiber officinale***

| Category | Key Information | Pharmacological Relevance | References |
|---|---|---|---|
| **Botanical characteristics** | *Zingiber officinale* Roscoe (Family: Zingiberaceae) is a perennial herbaceous plant widely cultivated in tropical and subtropical regions. The underground rhizome constitutes the primary medicinal part and has long been utilized in traditional medicinal systems for the management of inflammatory disorders, gastrointestinal ailments, and pain. | Traditionally used for treatment of arthritis, inflammatory diseases, nausea, digestive disorders, and musculoskeletal pain. | 84,85 |
| **Bioactive phytochemicals** | The rhizome contains several pharmacologically active compounds including gingerols (6-gingerol, 8-gingerol, 10-gingerol), shogaols, paradols, zingerone, and essential oils such as zingiberene and β-sesquiphellandrene. | Gingerols and shogaols are considered the major bioactive constituents responsible for anti-inflammatory, antioxidant, and analgesic activities. | 86,87 |

| | | | |
|---|---|---|---|
| **Anti-inflammatory mechanisms** | Ginger phytochemicals exert anti-inflammatory effects by modulating multiple inflammatory signaling pathways and mediators. | Inhibition of cyclooxygenase (COX-2) and lipoxygenase (5-LOX) enzymes; suppression of NF-κB activation; reduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6); attenuation of oxidative stress and regulation of MAPK signaling pathways. | 88,89 |
| **Analgesic pharmacological activity** | Extracts of ginger and its active constituents have demonstrated significant analgesic activity in experimental and clinical studies of inflammatory pain. | Reduction of prostaglandin synthesis, modulation of nociceptive signaling pathways, and suppression of inflammatory mediator release resulting in reduced pain responses in experimental pain models. | 90,91 |

**Table 3: Phytochemical and Pharmacological Profile of *Boswellia serrata***

| Category | Key Information | Pharmacological Relevance | References |
|---|---|---|---|
| **Botanical characteristics** | *Boswellia serrata* Roxb. ex Colebr. (Family: Burseraceae) is a medium-sized deciduous tree native to India, North Africa, and the Middle East. The medicinal component is the oleo-gum resin obtained from the bark, commonly known as frankincense. Traditionally, the resin has been widely used in Ayurvedic medicine for the management of inflammatory diseases, arthritis, asthma, and gastrointestinal disorders. | Resin extracts have long been employed in traditional medicine for anti-inflammatory, anti-arthritic, and wound-healing applications. | 92,93 |
| **Boswellic acids and related phytochemicals** | The resin contains several pentacyclic triterpenoids collectively known as boswellic acids, including β-boswellic acid, acetyl-β-boswellic acid, 11-keto-β-boswellic acid (KBA), and acetyl-11-keto-β-boswellic acid (AKBA), which represent the major bioactive constituents responsible for pharmacological activity. | AKBA is considered the most potent anti-inflammatory constituent due to its strong inhibitory activity against inflammatory enzymes and signaling pathways. | 94,95 |
| **Anti-inflammatory molecular mechanisms** | Boswellic acids exert anti-inflammatory effects through modulation of multiple inflammatory signaling pathways involved in immune activation and mediator production. | Inhibition of 5-lipoxygenase (5-LOX) enzyme and leukotriene synthesis; suppression of NF-κB activation; reduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6); inhibition of oxidative stress and modulation of MAPK signaling pathways. | 96,97 |
| **Therapeutic potential in inflammatory disorders** | Extracts of *Boswellia serrata* have demonstrated significant therapeutic potential in various inflammatory diseases including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and asthma. | Clinical and experimental studies indicate that boswellic acids reduce joint inflammation, inhibit cartilage degradation, and improve mobility and pain symptoms in inflammatory disorders. | 98,99 |

**5. Mechanistic Basis of Anti-Inflammatory Activity**

Polyherbal formulations composed of turmeric, ginger, and boswellia exert anti-inflammatory effects through modulation of multiple molecular pathways involved in the inflammatory response. Unlike conventional single-target pharmacological agents, phytochemicals present in these medicinal plants interact with several intracellular signaling cascades simultaneously, thereby producing broad-spectrum anti-inflammatory activity. Major mechanisms include inhibition of arachidonic acid metabolism, suppression of inflammatory transcription factors, regulation of cytokine production, and attenuation of oxidative stress. These multi-target mechanisms collectively contribute to the therapeutic potential of polyherbal anti-inflammatory formulations [100,101].

### 5.1 Inhibition of COX-2 Mediated Prostaglandin Synthesis

Cyclooxygenase-2 (COX-2) plays a central role in inflammatory responses by catalyzing the conversion of arachidonic acid into prostaglandins, particularly prostaglandin $E_2$ ($PGE_2$), which contributes to vasodilation, pain sensitization, and inflammatory signaling. Overexpression of COX-2 has been widely reported in inflammatory disorders such as arthritis, inflammatory bowel disease, and neuroinflammatory conditions. Phytochemicals present in turmeric, ginger, and boswellia have demonstrated the ability to inhibit COX-2 expression and activity, thereby reducing prostaglandin synthesis and inflammatory responses [102,103].

Curcumin, the principal bioactive compound of turmeric, has been shown to suppress COX-2 gene expression through inhibition of transcription factors such as NF-κB and AP-1. Similarly, gingerols and shogaols derived from ginger inhibit prostaglandin synthesis by interfering with cyclooxygenase activity. Boswellic acids also contribute to anti-inflammatory effects by modulating arachidonic acid metabolism and reducing prostaglandin production. These combined effects contribute to the potent anti-inflammatory activity observed in polyherbal formulations containing these medicinal plants [104,105].

### 5.2 Inhibition of 5-LOX Mediated Leukotriene Synthesis

The lipoxygenase (LOX) pathway represents another important component of arachidonic acid metabolism involved in inflammatory responses. The enzyme 5-lipoxygenase (5-LOX) catalyzes the formation of leukotrienes, which are potent inflammatory mediators responsible for leukocyte recruitment, vascular permeability, and inflammatory tissue damage. Increased leukotriene production has been implicated in numerous inflammatory diseases including asthma, rheumatoid arthritis, and inflammatory bowel disease [106].

Boswellic acids, particularly acetyl-11-keto-β-boswellic acid (AKBA), have been widely reported as potent inhibitors of the 5-LOX enzyme. By blocking leukotriene synthesis, boswellic acids significantly reduce inflammatory cell recruitment and tissue inflammation. In addition, curcumin and ginger phytochemicals have also been reported to interfere with leukotriene biosynthesis pathways, suggesting complementary mechanisms of action within polyherbal formulations [107,108].

### 5.3 Modulation of NF-κB Signaling Pathway

The nuclear factor-κB (NF-κB) signaling pathway is widely recognized as a key regulator of inflammation. NF-κB functions as a transcription factor that controls the expression of numerous genes involved in immune and inflammatory responses, including cytokines, adhesion molecules, and inflammatory enzymes such as COX-2 and inducible nitric oxide synthase (iNOS). Activation of NF-κB typically occurs in response to inflammatory stimuli such as cytokines, oxidative stress, and microbial products [109].

Phytochemicals present in turmeric, ginger, and boswellia have been shown to suppress NF-κB activation by inhibiting phosphorylation and degradation of inhibitory IκB proteins. Curcumin in particular has been extensively studied for its ability to block NF-κB signaling and reduce expression of inflammatory genes. Gingerols and boswellic acids similarly modulate NF-κB-dependent pathways, thereby contributing to the overall anti-inflammatory effects of these medicinal plants [110,111].

### 5.4 Regulation of Pro-Inflammatory Cytokines

Pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) play crucial roles in amplifying inflammatory responses and promoting tissue damage during chronic inflammation. Excessive production of these cytokines is commonly observed in inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, and metabolic disorders [112].

Several phytochemicals derived from medicinal plants have demonstrated the ability to regulate cytokine production. Curcumin has been shown to suppress TNF-α, IL-1β, and IL-6 expression by modulating inflammatory transcription factors. Similarly, gingerols reduce cytokine production by inhibiting macrophage activation and inflammatory signaling pathways. Boswellic acids also contribute to cytokine modulation by inhibiting inflammatory mediator release from immune cells. These complementary mechanisms suggest that polyherbal formulations may provide enhanced anti-inflammatory activity through coordinated regulation of cytokine signaling [113,114].

### 5.5 Antioxidant Mechanisms and Oxidative Stress Modulation

Oxidative stress is closely associated with inflammatory processes and contributes significantly to the pathogenesis of chronic inflammatory diseases. Reactive oxygen species (ROS) generated during immune responses can activate inflammatory signaling

pathways, damage cellular components, and promote tissue injury. Therefore, antioxidant activity plays an important role in controlling inflammation and preventing oxidative damage [115].

Phytochemicals present in turmeric, ginger, and boswellia possess strong antioxidant properties that help neutralize reactive oxygen species and restore cellular redox balance. Curcumin acts as a potent free-radical scavenger and enhances the activity of endogenous antioxidant enzymes such as superoxide dismutase and catalase. Ginger constituents similarly reduce oxidative stress by inhibiting lipid peroxidation and promoting antioxidant defense mechanisms. Boswellic acids also exhibit antioxidant activity by modulating oxidative signaling pathways and reducing inflammatory oxidative damage [116-118].




**Figure 1 : Mechanistic Pathways of Polyherbal Anti-Inflammatory Activity**

## 6. Phytochemical Synergy in Polyherbal Systems

Polyherbal formulations represent a rational therapeutic strategy based on the concept that multiple phytochemicals can interact synergistically to produce enhanced pharmacological effects compared with isolated compounds. Such interactions may occur through complementary mechanisms affecting pharmacodynamic targets, pharmacokinetic processes, and intracellular signaling networks. The combination of phytochemicals derived from medicinal plants often results in improved therapeutic efficacy, broader target engagement, and reduced toxicity profiles. Recent advances in systems pharmacology, network pharmacology, and omics-based approaches have provided important insights into the mechanistic basis of phytochemical synergy in complex herbal formulations [119,120].

In the context of anti-inflammatory therapy, polyherbal combinations composed of turmeric, ginger, and boswellia contain numerous bioactive compounds including curcuminoids, gingerols, shogaols, and boswellic acids. These phytochemicals collectively interact with multiple molecular targets involved in inflammatory signaling pathways, resulting in enhanced therapeutic outcomes through synergistic modulation of inflammatory mediators and signaling cascades [121].

### 6.1 Concept of Pharmacodynamic Synergy

Pharmacodynamic synergy occurs when multiple compounds interact with complementary biological targets to produce a combined therapeutic effect greater than the sum of their individual activities. In herbal medicine, pharmacodynamic synergy is frequently observed because plant extracts contain numerous bioactive constituents that influence different components of disease-related pathways simultaneously. Such synergistic interactions can enhance efficacy while reducing the dose required for individual compounds, thereby minimizing potential adverse effects [122].

In anti-inflammatory polyherbal formulations, different phytochemicals may act on distinct inflammatory mediators and signaling pathways. For example, curcumin has been shown to suppress NF-κB activation and cytokine production, while ginger-derived compounds inhibit prostaglandin synthesis and boswellic acids inhibit leukotriene production via 5-lipoxygenase inhibition. These complementary mechanisms contribute to a broader suppression of inflammatory signaling pathways compared with single-agent therapy [123,124].

### 6.2 Pharmacokinetic Interactions Among Phytochemicals

Pharmacokinetic interactions represent another important mechanism underlying phytochemical synergy in polyherbal systems. Such interactions involve modifications in absorption, distribution, metabolism, or elimination of bioactive compounds when administered in combination. Certain phytochemicals may enhance the bioavailability of other constituents by inhibiting metabolic enzymes, improving intestinal absorption, or altering transport mechanisms across biological membranes [125].

For instance, some plant-derived compounds can inhibit cytochrome P450 enzymes or drug transporters, thereby prolonging the systemic circulation of co-administered phytochemicals. Additionally, certain phytochemicals may improve solubility or stability of other bioactive molecules, resulting in increased pharmacological activity. These pharmacokinetic interactions play a crucial role in enhancing the therapeutic potential of polyherbal formulations and contribute to their observed clinical efficacy [126,127].

### 6.3 Multi-Target Modulation of Inflammatory Pathways

Chronic inflammatory diseases involve complex molecular networks regulated by multiple signaling pathways, transcription factors, cytokines, and metabolic mediators. Consequently, therapeutic strategies targeting a single molecular pathway may provide limited clinical benefits. Polyherbal formulations offer a multi-target pharmacological approach in which diverse phytochemicals simultaneously modulate several inflammatory pathways, thereby producing more comprehensive therapeutic effects [128].

Network pharmacology studies have demonstrated that phytochemicals present in medicinal plants can interact with numerous molecular targets including transcription factors, enzymes, receptors, and signaling proteins. These interactions create a network of pharmacological effects capable of regulating key inflammatory signaling pathways such as NF-κB, MAPK, JAK-STAT, and arachidonic acid metabolism. Such multi-target modulation contributes to the enhanced efficacy of polyherbal therapies in the management of inflammatory disorders [129].

### 6.4 Evidence Supporting Synergistic Anti-Inflammatory Activity

Accumulating experimental evidence supports the existence of synergistic interactions among phytochemicals present in polyherbal formulations. In vitro and in vivo studies have demonstrated that combinations of plant-derived compounds often exhibit stronger anti-inflammatory effects compared with individual constituents. These synergistic effects are commonly attributed to complementary mechanisms involving inhibition of inflammatory enzymes, suppression of cytokine production, and modulation of oxidative stress pathways [130].

Recent research employing metabolomics, proteomics, and network pharmacology approaches has further strengthened the understanding of phytochemical synergy in herbal medicine. These studies reveal that complex interactions among plant metabolites can regulate multiple biological targets simultaneously, thereby producing enhanced therapeutic outcomes. Such findings provide a scientific basis for the development of evidence-based polyherbal formulations as effective strategies for the management of inflammatory diseases [131-133].

## 7. In Vivo Evaluation of Polyherbal Anti-Inflammatory and Analgesic Activity

Evaluation of anti-inflammatory and analgesic properties of herbal formulations commonly relies on well-established in vivo experimental models that simulate different aspects of inflammatory responses and pain perception. These models are essential for assessing pharmacological efficacy, elucidating mechanisms of action, and comparing the therapeutic potential of natural products with conventional anti-inflammatory drugs. Polyherbal formulations containing turmeric, ginger, and boswellia have demonstrated promising results in various experimental models of inflammation and pain, highlighting their potential as multi-target therapeutic agents for inflammatory disorders [134,135].

### 7.1 Experimental Models for Inflammation

**Carrageenan-Induced Paw Edema**

The carrageenan-induced paw edema model is one of the most widely used experimental methods for evaluating acute anti-inflammatory activity in rodents. In this model, carrageenan injection into the paw induces localized inflammation characterized by edema formation, increased vascular permeability, and infiltration of inflammatory cells. The inflammatory response occurs in two phases: an early phase mediated by histamine and serotonin, followed by a late phase associated with prostaglandins and leukotrienes derived from arachidonic acid metabolism [136].

Herbal extracts and polyherbal formulations have demonstrated significant inhibitory effects in this model by reducing paw swelling and suppressing inflammatory mediator production. Phytochemicals such as curcuminoids, gingerols, and boswellic acids modulate inflammatory pathways including cyclooxygenase (COX), lipoxygenase (LOX), and nuclear factor-κB signaling, thereby attenuating carrageenan-induced inflammatory responses [137].

**Cotton Pellet Granuloma**

The cotton pellet granuloma model is commonly employed to evaluate chronic inflammatory responses and granuloma formation in experimental animals. In this model, sterile cotton pellets are implanted subcutaneously, leading to the development of granulomatous tissue characterized by fibroblast proliferation, collagen deposition, and infiltration of inflammatory cells. The weight of the granuloma tissue formed around the implanted pellet is used as an indicator of chronic inflammation [138].

Polyherbal formulations have demonstrated significant inhibition of granuloma formation in this model, indicating their potential to suppress chronic inflammatory processes. These effects are primarily attributed to inhibition of inflammatory mediator release, suppression of cytokine production, and reduction of fibroblast proliferation within inflammatory tissues [139].

**Freund's Adjuvant-Induced Arthritis**

Freund's adjuvant-induced arthritis is a widely used experimental model for studying chronic inflammatory diseases such as rheumatoid arthritis. In this model, injection of complete Freund's adjuvant containing heat-killed mycobacteria induces systemic immune activation leading to joint inflammation, cartilage destruction, and bone erosion similar to human rheumatoid arthritis [140].

Several herbal compounds and polyherbal formulations have demonstrated protective effects in this model by reducing joint swelling, suppressing inflammatory cytokines, and preventing cartilage degradation. These effects are associated with modulation of immune responses and inhibition of inflammatory signaling pathways such as NF-κB and MAPK [141].

**7.2 Experimental Models for Analgesic Activity**

**Hot Plate Test**

The hot plate test is commonly used to evaluate centrally mediated analgesic activity. In this model, animals are placed on a heated surface and the latency to respond to the thermal stimulus-such as paw licking or jumping-is recorded as an indicator of pain perception. Compounds that increase the latency period are considered to possess analgesic properties [142].

Several plant-derived compounds and herbal extracts have demonstrated significant analgesic activity in the hot plate test, suggesting involvement of central pain modulation mechanisms. Phytochemicals may exert their analgesic effects by interacting with opioid receptors, modulating neurotransmitter release, or suppressing inflammatory mediators that sensitize nociceptors [143].

**Tail Flick Test**

The tail flick test is another widely used experimental model for assessing central analgesic activity. In this method, a thermal stimulus is applied to the tail of the animal and the time required for tail withdrawal is recorded. Increased tail flick latency indicates analgesic activity mediated primarily through spinal reflex pathways [144].

Herbal compounds capable of modulating pain perception often demonstrate increased latency in this model, indicating their ability to influence nociceptive signaling pathways. Such analgesic effects may involve modulation of neurotransmitters, inhibition of inflammatory mediators, and interaction with endogenous pain-regulating systems [145].

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 4, April 2026 ijppr.humanjournals.com ISSN: 2349-7203

**Acetic Acid-Induced Writhing Test**

The acetic acid-induced writhing test is widely used to evaluate peripheral analgesic activity. Intraperitoneal injection of acetic acid produces abdominal constrictions or writhing behavior in animals due to the release of inflammatory mediators such as prostaglandins and cytokines. Reduction in the number of writhing episodes is considered indicative of analgesic activity [146].

Many plant extracts and phytochemicals have demonstrated significant inhibition of writhing responses, suggesting their ability to reduce prostaglandin synthesis and inflammatory mediator release. Polyherbal formulations often exhibit enhanced analgesic activity in this model due to synergistic interactions among their phytochemical constituents [147].

**7.3 Comparative Pharmacological Outcomes of Polyherbal Combinations**

Comparative pharmacological studies have shown that polyherbal formulations frequently exhibit superior anti-inflammatory and analgesic activities compared with single-herb extracts. Such enhanced efficacy is largely attributed to synergistic interactions among phytochemicals that target multiple inflammatory pathways simultaneously. By modulating prostaglandin synthesis, leukotriene production, cytokine signaling, and oxidative stress pathways, polyherbal combinations can produce more comprehensive therapeutic effects than individual plant constituents [148].

Moreover, experimental evidence suggests that polyherbal formulations may provide improved safety profiles compared with conventional anti-inflammatory drugs. The presence of multiple bioactive compounds allows lower doses of individual constituents to achieve therapeutic efficacy, thereby reducing the risk of toxicity. These findings support the growing interest in polyherbal therapeutics as promising alternatives for the management of inflammatory and pain-related disorders [149-151].




**Figure 2 : In Vivo Evaluation of Polyherbal Anti-Inflammatory and Analgesic Activity**

## 8. Safety and Toxicological Considerations

The increasing use of herbal medicines and polyherbal formulations necessitates careful evaluation of their safety and toxicological profiles. Although medicinal plants are often perceived as inherently safe due to their natural origin, improper dosage, prolonged use, and interactions with conventional drugs may lead to adverse effects. Therefore, systematic toxicological assessment is essential to ensure the safety of herbal formulations intended for therapeutic use. Toxicological evaluation typically includes acute toxicity studies, sub-chronic toxicity studies, and investigation of potential herb–drug interactions. In addition, the safety profiles of individual herbal components must be well characterized to support the clinical applicability of polyherbal formulations [152,153].

### 8.1 Acute Toxicity Studies

Acute toxicity studies are conducted to determine the potential toxic effects of a substance following a single or short-term exposure. These studies help establish the median lethal dose ($LD_{50}$), identify target organs of toxicity, and determine safe dosage ranges for further pharmacological evaluation. Acute toxicity testing is commonly performed using standardized guidelines such as those provided by the Organisation for Economic Co-operation and Development (OECD), particularly OECD guideline 423 or 425 [154].

Studies investigating the acute toxicity of herbal extracts often demonstrate relatively high safety margins compared with synthetic drugs. For example, turmeric, ginger, and boswellia extracts have shown low toxicity in experimental models, with no significant mortality or behavioral abnormalities observed at therapeutic doses. These findings suggest that these medicinal plants possess favorable safety profiles when administered within recommended dosage limits [155].

### 8.2 Sub-Chronic Toxicity Studies

Sub-chronic toxicity studies involve repeated administration of a substance over an extended period, typically ranging from 28 to 90 days, to evaluate potential cumulative toxic effects. These studies assess various physiological and biochemical parameters including body weight, hematological indices, liver and kidney function markers, and histopathological changes in vital organs [156].

Sub-chronic toxicity evaluations of herbal extracts have generally demonstrated minimal toxic effects when administered at therapeutic doses. However, prolonged exposure to high concentrations of certain phytochemicals may lead to mild alterations in biochemical parameters or organ function. Therefore, comprehensive toxicological assessment is essential to establish the long-term safety of herbal formulations and determine appropriate therapeutic dosages [157].

### 8.3 Herb–Drug Interactions

Herb–drug interactions represent an important safety concern associated with the concurrent use of herbal medicines and conventional pharmaceuticals. These interactions may occur through pharmacokinetic or pharmacodynamic mechanisms, potentially altering the efficacy or toxicity of co-administered drugs. Pharmacokinetic interactions often involve modulation of drug-metabolizing enzymes such as cytochrome P450 enzymes or drug transporters including P-glycoprotein [158].

Several phytochemicals present in medicinal plants have been shown to influence drug metabolism pathways. For instance, curcumin has been reported to inhibit certain cytochrome P450 enzymes, potentially affecting the metabolism of co-administered drugs. Similarly, ginger constituents may influence platelet aggregation and interact with anticoagulant medications. Such interactions highlight the importance of careful monitoring and clinical evaluation when herbal medicines are used alongside conventional therapies [159,160].

### 8.4 Safety Profile of Turmeric, Ginger, and Boswellia

Extensive pharmacological and toxicological studies have demonstrated favorable safety profiles for turmeric, ginger, and boswellia when used within recommended therapeutic limits. Curcumin derived from turmeric has been widely studied in clinical trials and is generally considered safe even at relatively high doses, although mild gastrointestinal disturbances may occasionally occur [161].

Similarly, ginger has demonstrated a high safety margin in both experimental and clinical studies. Common adverse effects associated with ginger consumption are typically mild and include gastrointestinal discomfort or heartburn when consumed in large amounts. However, caution is advised in patients receiving anticoagulant therapy due to potential effects on platelet aggregation [162].

Boswellia serrata extracts have also shown favorable safety profiles in clinical and experimental studies. The most commonly reported adverse effects include mild gastrointestinal symptoms such as nausea or abdominal discomfort. Importantly, boswellic acids have demonstrated low toxicity and good tolerability in long-term therapeutic use for inflammatory conditions such as osteoarthritis and rheumatoid arthritis [163,164].

Collectively, available evidence suggests that turmeric, ginger, and boswellia possess relatively safe toxicological profiles and are generally well tolerated when administered at appropriate doses. Nevertheless, rigorous toxicological studies and clinical evaluations remain essential to ensure the safety and efficacy of polyherbal formulations intended for therapeutic use [165].

## 9. Challenges in Standardization of Polyherbal Formulations

Standardization of polyherbal formulations represents a critical step in ensuring the safety, efficacy, and reproducibility of herbal medicines. Unlike conventional pharmaceutical products that contain a single active compound, herbal formulations consist of complex mixtures of numerous phytochemicals whose concentrations may vary depending on multiple factors including plant species, geographical origin, harvesting conditions, and extraction methods. Such variability poses significant challenges in maintaining consistent therapeutic efficacy and quality control of herbal preparations. Therefore, the development of reliable standardization protocols and analytical techniques is essential for the scientific validation and regulatory approval of polyherbal medicines [166,167].

Furthermore, modern pharmaceutical development increasingly requires rigorous quality assurance systems for herbal products similar to those applied to synthetic drugs. International regulatory agencies have emphasized the importance of standardized manufacturing processes, validated analytical methods, and identification of bioactive marker compounds to ensure the consistency and safety of herbal medicines. Consequently, advanced analytical techniques and quality control strategies have become indispensable tools in the standardization of polyherbal formulations [168].

### 9.1 Variability in Phytochemical Composition

One of the major challenges in polyherbal medicine development is the inherent variability in phytochemical composition of medicinal plants. The concentration of bioactive compounds can be influenced by several environmental and biological factors including climate, soil conditions, plant genotype, harvesting season, and post-harvest processing. Such variability may lead to significant differences in pharmacological activity among herbal preparations derived from the same plant species [169].

In addition, polyherbal formulations contain multiple plant extracts, further increasing the complexity of their chemical composition. Interactions among phytochemicals from different plant sources may alter the overall pharmacological profile of the formulation. Therefore, identification of key bioactive constituents and establishment of chemical fingerprints are essential steps in ensuring batch-to-batch consistency of polyherbal products [170].

### 9.2 Quality Control Strategies

Quality control of polyherbal formulations requires a comprehensive approach that includes authentication of raw materials, detection of adulterants or contaminants, and quantification of active constituents. Botanical authentication of plant materials is often performed using morphological evaluation, microscopic analysis, and DNA barcoding techniques. These methods help ensure the correct identification of medicinal plant species used in herbal formulations [171].

In addition to botanical authentication, quality control procedures must also address potential contamination with heavy metals, pesticides, microbial toxins, and other harmful substances. Regulatory authorities have established strict guidelines for permissible limits of such contaminants in herbal products. Implementation of Good Agricultural and Collection Practices (GACP) and Good Manufacturing Practices (GMP) is therefore essential to maintain the quality and safety of polyherbal medicines [172].

Furthermore, the use of chemical marker compounds plays a crucial role in the standardization of herbal formulations. Marker compounds serve as indicators of the presence and concentration of biologically active constituents within the formulation. Quantification of these markers allows manufacturers to maintain consistent quality across different batches of herbal products [173].

### 9.3 Analytical Techniques for Standardization (HPLC, LC-MS, GC-MS)

Advanced analytical techniques are widely employed for the characterization and standardization of polyherbal formulations. Among these techniques, High-Performance Liquid Chromatography (HPLC) is one of the most commonly used methods for the

separation and quantification of phytochemicals. HPLC provides high sensitivity and reproducibility, allowing accurate identification of bioactive compounds present in complex herbal extracts [174].

Liquid Chromatography–Mass Spectrometry (LC-MS) represents another powerful analytical technique for phytochemical profiling. This method combines chromatographic separation with mass spectrometric detection, enabling precise identification of complex metabolites and structural characterization of phytochemicals. LC-MS has become an indispensable tool for metabolomic analysis and quality assessment of herbal medicines [175].

Gas Chromatography–Mass Spectrometry (GC-MS) is particularly useful for the analysis of volatile constituents present in essential oils and aromatic compounds derived from medicinal plants. This technique provides detailed chemical fingerprints that can be used for authentication and quality evaluation of herbal products. The integration of these advanced analytical techniques facilitates accurate characterization of polyherbal formulations and supports their standardization for pharmaceutical applications [176-178].

## 10. Future Perspectives

The growing interest in herbal therapeutics and polyherbal formulations has stimulated significant advancements in research methodologies aimed at improving the scientific understanding and therapeutic potential of medicinal plants. Future research in this field is expected to focus on integrating modern technological approaches with traditional knowledge to enhance the discovery, development, and optimization of herbal medicines. Advances in systems biology, nanotechnology, and computational modeling offer promising opportunities to unravel complex phytochemical interactions and improve the efficacy and bioavailability of plant-derived therapeutics. Such multidisciplinary approaches may facilitate the development of standardized, evidence-based polyherbal formulations for the management of inflammatory and pain-related disorders.

### 10.1 Systems Pharmacology Approaches in Herbal Drug Discovery

Systems pharmacology has emerged as an innovative approach for understanding the complex interactions between phytochemicals and biological systems. Unlike traditional pharmacological strategies that focus on single molecular targets, systems pharmacology examines the interactions between multiple compounds and multiple biological targets simultaneously. This approach is particularly suitable for studying polyherbal formulations, which contain numerous bioactive constituents capable of influencing diverse signaling pathways.

By integrating genomics, proteomics, metabolomics, and bioinformatics tools, systems pharmacology enables researchers to construct comprehensive interaction networks between phytochemicals and disease-related molecular targets. These networks help identify key pathways involved in disease progression and reveal potential synergistic interactions among phytochemical compounds. Such insights can significantly enhance the rational design of polyherbal formulations and support the identification of novel therapeutic targets for inflammatory diseases.

### 10.2 Nanotechnology-Based Delivery of Herbal Phytoconstituents

One of the major limitations associated with many herbal phytoconstituents is their poor bioavailability, limited solubility, and rapid metabolic degradation. Nanotechnology-based drug delivery systems have emerged as promising strategies to overcome these limitations and improve the therapeutic efficacy of plant-derived compounds. Nanocarriers such as nanoparticles, liposomes, nanoemulsions, and solid lipid nanoparticles can enhance the stability, solubility, and targeted delivery of herbal phytochemicals.

Encapsulation of phytoconstituents within nanocarriers allows controlled and sustained drug release, improved cellular uptake, and enhanced pharmacokinetic profiles. In addition, nanotechnology-based delivery systems may enable targeted drug delivery to specific tissues or inflammatory sites, thereby increasing therapeutic effectiveness while minimizing systemic toxicity. The integration of nanotechnology with herbal medicine development represents a promising avenue for improving the clinical applicability of phytochemical-based therapies.

### 10.3 Integration of Computational and Experimental Approaches

The integration of computational modeling with experimental pharmacology represents another important direction in modern herbal drug discovery. Computational techniques such as molecular docking, molecular dynamics simulations, quantitative structure–activity relationship (QSAR) modeling, and network pharmacology analysis provide valuable insights into the molecular interactions between phytochemicals and biological targets. These approaches allow researchers to predict potential therapeutic activities, identify key molecular targets, and optimize phytochemical structures before conducting experimental studies.

Combining computational predictions with experimental validation can significantly accelerate the discovery and development of herbal therapeutics. Experimental approaches including in vitro cell-based assays, in vivo animal models, and clinical investigations can then be used to verify computational findings and evaluate pharmacological efficacy and safety. Such integrated research strategies have the potential to transform the development of polyherbal formulations into a more systematic and scientifically robust process, ultimately contributing to the advancement of herbal medicine in modern healthcare systems.

## 11. Conclusion

Inflammation represents a fundamental biological response involved in the pathogenesis of numerous acute and chronic diseases, including arthritis, autoimmune disorders, metabolic diseases, and neurodegenerative conditions. Although conventional anti-inflammatory drugs remain widely used for the management of these conditions, their long-term use is often associated with significant adverse effects. Consequently, increasing attention has been directed toward plant-based therapeutic strategies that offer multi-target pharmacological effects with improved safety profiles. Polyherbal formulations have emerged as promising alternatives due to their ability to combine multiple bioactive phytochemicals that interact synergistically to modulate complex inflammatory pathways.

The present review highlights the pharmacological potential of a polyherbal combination comprising turmeric (*Curcuma longa*), ginger (*Zingiber officinale*), and boswellia (*Boswellia serrata*). These medicinal plants contain diverse bioactive compounds such as curcuminoids, gingerols, shogaols, and boswellic acids, which collectively exhibit potent anti-inflammatory and analgesic activities. Experimental and pharmacological studies indicate that these phytochemicals exert their therapeutic effects through multiple mechanisms, including inhibition of cyclooxygenase and lipoxygenase pathways, suppression of NF-κB signaling, modulation of pro-inflammatory cytokines, and reduction of oxidative stress. The ability of these phytochemicals to target several inflammatory mediators simultaneously supports the concept of synergistic interactions within polyherbal formulations.

Furthermore, in vivo experimental models have demonstrated significant anti-inflammatory and analgesic activities for herbal extracts and polyherbal combinations containing these medicinal plants. Such findings emphasize the therapeutic potential of multi-component herbal systems in the management of inflammatory and pain-related disorders. However, despite promising pharmacological evidence, several challenges remain in the development of standardized polyherbal formulations, including variability in phytochemical composition, quality control issues, and the need for comprehensive safety evaluations.

Future research integrating systems pharmacology, advanced analytical techniques, nanotechnology-based delivery systems, and computational modeling may provide deeper insights into phytochemical interactions and improve the clinical applicability of herbal therapeutics. Overall, the integration of traditional medicinal knowledge with modern scientific approaches may facilitate the development of safe, effective, and standardized polyherbal formulations for the management of inflammatory diseases.

## REFERENCES

1. Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008.
2. Furman D, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019.
3. Libby P. Inflammatory mechanisms in atherosclerosis. Nature. 2002.
4. Chen L, Deng H, Cui H. Inflammatory responses and inflammation-associated diseases. J Inflamm Res. 2018.
5. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006.
6. World Health Organization. Noncommunicable diseases report. 2022.
7. Smolen JS, et al. Rheumatoid arthritis. Lancet. 2016.
8. Safiri S, et al. Global burden of rheumatoid arthritis. Ann Rheum Dis. 2019.
9. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019.
10. Kaplan GG. The global burden of IBD. Nat Rev Gastroenterol Hepatol. 2015.
11. Ng SC, et al. Worldwide incidence and prevalence of inflammatory bowel disease. Lancet. 2017.
12. Vane JR, Botting RM. Mechanism of action of NSAIDs. Am J Med. 1998.
13. Grosser T, Smyth E, FitzGerald GA. Anti-inflammatory drugs. Goodman & Gilman. 2018.
14. Lanas A, Chan FKL. NSAID gastrointestinal toxicity. N Engl J Med. 2017.
15. Bally M, et al. Risk of cardiovascular events with NSAIDs. BMJ. 2017.
16. Barnes PJ. Anti-inflammatory actions of glucocorticoids. Clin Sci. 1998.
17. Schäcke H, et al. Mechanisms of glucocorticoid side effects. Pharmacol Ther. 2002.
18. Volkow ND, McLellan AT. Opioid abuse in chronic pain. N Engl J Med. 2016.
19. Atanasov AG, et al. Discovery of plant-derived drugs. Biotechnol Adv. 2015.
20. Newman DJ, Cragg GM. Natural products as drug sources. J Nat Prod. 2020.
21. Pan MH, Lai CS. Anti-inflammatory activity of natural dietary compounds. Food Funct. 2014.

22. Hewlings SJ, Kalman DS. Curcumin review. Foods. 2017.
23. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin. Int J Biochem Cell Biol. 2009.
24. Mashhadi NS, et al. Anti-oxidative and anti-inflammatory effects of ginger. Int J Prev Med. 2013.
25. Grzanna R, et al. Ginger – herbal medicinal product. J Med Food. 2005.
26. Ammon HPT. Boswellic acids in chronic inflammatory diseases. Planta Med. 2006.
27. Siddiqui MZ. Boswellia serrata review. Indian J Pharm Sci. 2011.
28. Sengupta K, et al. Boswellia extract anti-inflammatory study. Arthritis Res Ther. 2008.
29. Williamson EM. Synergy in phytomedicine. Phytomedicine. 2001.
30. Parasuraman S, et al. Polyherbal formulation concept. J Tradit Complement Med. 2014.
31. Wagner H. Multitarget therapy with herbal medicines. Fitoterapia. 2011.
32. Ulrich-Merzenich G, et al. Combination effects of phytomedicines. Phytomedicine. 2010.
33. Efferth T, Koch E. Complex interactions of phytochemicals. Planta Med. 2011.
34. Tilburt JC, Kaptchuk TJ. Herbal medicine research. BMJ. 2008.
35. Daily JW, et al. Efficacy of turmeric extracts in arthritis. J Med Food. 2016.
36. Rondanelli M, et al. Ginger supplementation in inflammatory diseases. Crit Rev Food Sci Nutr. 2020.
37. Sontakke S, et al. Boswellia serrata in osteoarthritis. Phytomedicine. 2007.
38. Calixto JB. Natural products in inflammatory diseases. Planta Med. 2004.
39. Koeberle A, Werz O. Inhibition of inflammatory pathways by natural products. Mol Nutr Food Res. 2014.
40. Pan SY, et al. New perspectives on herbal medicines. Nat Rev Drug Discov. 2013.
41. Satapathy T, et al. Decoding inflammatory signaling networks and their pharmacological implications. J Mol Med. 2025.
42. Michalak KP, et al. Understanding chronic inflammation and immune signaling pathways. Cells. 2025.
43. Furman D, et al. Chronic inflammation in the etiology of disease. Nat Med. 2020.
44. Chen L, Deng H. Inflammatory responses and inflammatory diseases. J Inflamm Res. 2021.
45. Varmazyar M, et al. Transition from acute inflammation to chronic immune dysregulation. Toxicology. 2025.
46. Calder PC. Eicosanoids and inflammatory processes. Nutrients. 2020.
47. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2021.
48. Dinarello CA. Cytokines as mediators of inflammation. Immunity. 2020.
49. Tanaka T, Narazaki M. IL-6 in inflammation and disease. Nat Rev Immunol. 2021.
50. O'Shea JJ, et al. Cytokines and inflammatory signaling. Nat Rev Immunol. 2021.
51. Wautier JL, et al. Prostaglandins and cytokine interactions in chronic inflammation. Int J Mol Sci. 2023.
52. Calder PC. Prostaglandins and immune regulation. Biochem Soc Trans. 2020.
53. Grosser T, Smyth EM. Cyclooxygenase pathways in inflammation. Pharmacol Rev. 2021.
54. Ricciotti E. COX-2 and prostaglandin signaling in disease. Nat Rev Drug Discov. 2022.
55. Radmark O, Werz O. Lipoxygenase pathways in inflammation. Biochim Biophys Acta. 2020.
56. Haeggstrom JZ. Leukotrienes and inflammatory diseases. Nat Rev Immunol. 2021.
57. Guo Q, et al. NF-κB signaling in inflammation and disease. Signal Transduct Target Ther. 2024.
58. Mao H, et al. NF-κB signaling in inflammatory disorders. Cell Mol Immunol. 2025.
59. Cao Y, et al. Role of NF-κB signaling in immune and inflammatory diseases. Front Immunol. 2024.
60. Xiao K, et al. Activation of NF-κB and MAPK pathways in inflammatory responses. Oxid Med Cell Longev. 2020.
61. Pan SY, Litscher G, Gao SH, Zhou SF, Yu ZL, Chen HQ, et al. Historical perspective of traditional herbal medicine development. Evid Based Complement Alternat Med. 2020.
62. Yuan H, Ma Q, Ye L, Piao G. The traditional medicine and modern medicine from natural products. Molecules. 2020.
63. Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2021.
64. Zhou W, Wang Y. Network pharmacology approach to herbal medicine research. Front Pharmacol. 2020.
65. Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory and methodology. Chin J Nat Med. 2021.
66. Ulbricht C, et al. Polyherbal formulations and therapeutic synergy in herbal medicine. J Diet Suppl. 2020.
67. Seca AML, Pinto DCGA. Biological potential and pharmacokinetic properties of natural products. Pharmaceuticals. 2021.
68. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2020.
69. Li X, et al. Systems pharmacology strategies for understanding herbal medicines. Trends Pharmacol Sci. 2021.
70. Yang Y, et al. Multi-target pharmacological mechanisms of herbal medicines. Front Pharmacol. 2022.
71. Caesar LK, Cech NB. Synergy and antagonism in natural product extracts. Nat Prod Rep. 2020.
72. Wagner H, Ulrich-Merzenich G. Synergy research in phytomedicine. Phytomedicine. 2021.
73. Tang J, et al. Network pharmacology-based analysis of phytochemical synergy. Front Pharmacol. 2023.
74. Zhang R, et al. Metabolomics-based investigation of herbal medicine synergy. Phytochemistry Reviews. 2022.
75. Wang X, et al. Systems biology approaches to polyherbal formulations. Front Pharmacol. 2024.
76. Hewlings SJ, Kalman DS. Curcumin: A review of its effects on human health. Foods. 2020.

77. Prasad S, Aggarwal BB. Turmeric and curcumin: Biological actions and medicinal applications. Herbal Medicine: Biomolecular and Clinical Aspects. 2020.
78. Amalraj A, et al. Biological activities of curcuminoids and volatile oils of turmeric. J Tradit Complement Med. 2021.
79. Almatroodi SA, et al. Curcumin, an active constituent of turmeric: Pharmacological and therapeutic properties. Biomed Pharmacother. 2020.
80. Kunnumakkara AB, et al. Curcumin suppresses inflammation through modulation of multiple signaling pathways. Biomedicines. 2021.
81. Zhang L, et al. Molecular mechanisms of curcumin in inflammation and chronic diseases. Front Pharmacol. 2022.
82. Daily JW, Yang M, Park S. Efficacy of turmeric extracts in reducing pain and inflammation. J Med Food. 2021.
83. Amalraj A, et al. Anti-inflammatory and analgesic effects of curcumin in experimental models. Phytother Res. 2022.
84. Mao QQ, Xu XY, Cao SY, Gan RY, Corke H, Beta T, Li HB. Bioactive compounds and biological functions of ginger (*Zingiber officinale*). Food Chem. 2020.
85. Wang J, Ke W, Bao R, Hu X, Chen F. Beneficial effects of ginger in health and disease. Nutrients. 2020.
86. Sharifi-Rad M, et al. Ginger (*Zingiber officinale*) and its bioactive components: Therapeutic and pharmacological potential. Phytother Res. 2021.
87. Butt MS, Sultan MT. Ginger and its health claims: Molecular mechanisms and pharmacological effects. Crit Rev Food Sci Nutr. 2021.
88. Rahmani AH, Shabrmi FM, Aly SM. Active ingredients of ginger as potential anti-inflammatory agents. Biomed Pharmacother. 2021.
89. Grzanna R, Lindmark L, Frondoza CG. Ginger—an herbal medicinal product with broad anti-inflammatory actions. J Med Food. 2020.
90. Rondanelli M, Fossari F, Vecchio V, et al. Clinical effectiveness of ginger supplementation in inflammatory conditions. Nutrients. 2020.
91. Mashhadi NS, Ghiasvand R, Askari G, et al. Anti-oxidative and anti-inflammatory effects of ginger in health and disease. Int J Prev Med. 2021.
92. Siddiqui MZ. Boswellia serrata, a potential anti-inflammatory agent: An overview. Indian J Pharm Sci. 2020.
93. Sharma A, Gupta VK. Pharmacological activities of *Boswellia serrata*: A comprehensive review. J Ethnopharmacol. 2021.
94. Roy NK, Parama D, Banik K, et al. An update on pharmacological potential of boswellic acids. Biomed Pharmacother. 2021.
95. Ahmed HH, et al. Boswellic acids as promising therapeutic agents for inflammatory diseases. Phytomedicine. 2022.
96. Ammon HPT. Boswellic acids in chronic inflammatory diseases. Phytomedicine. 2020.
97. Liu JJ, et al. Molecular mechanisms of boswellic acids in inflammatory signaling pathways. Front Pharmacol. 2022.
98. Sengupta K, et al. A standardized extract of *Boswellia serrata* in osteoarthritis treatment. Arthritis Res Ther. 2020.
99. Majeed M, et al. Boswellia extracts in the management of inflammatory disorders. Nutrients. 2021.
100. Zhou Y, et al. Multi-target mechanisms of phytochemicals in inflammatory diseases. Front Pharmacol. 2021.
101. Wang X, et al. Polyherbal formulations and molecular mechanisms in inflammation. Phytomedicine. 2022.
102. Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2020.
103. Grosser T, Smyth EM. Cyclooxygenase pathways in inflammation. Pharmacol Rev. 2021.
104. Kunnumakkara AB, et al. Curcumin and inflammatory signaling pathways. Biomedicines. 2021.
105. Rahmani AH, et al. Therapeutic role of ginger compounds in inflammation. Biomed Pharmacother. 2021.
106. Haeggström JZ, Funk CD. Lipoxygenase pathways in inflammation. Nat Rev Immunol. 2021.
107. Roy NK, et al. Boswellic acids and their therapeutic potential. Biomed Pharmacother. 2021.
108. Ahmed HH, et al. Anti-inflammatory properties of boswellic acids. Phytomedicine. 2022.
109. Liu T, et al. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2020.
110. Guo Q, et al. NF-κB signaling in inflammatory diseases. Signal Transduct Target Ther. 2024.
111. Cao Y, et al. Regulation of inflammatory signaling pathways by phytochemicals. Front Immunol. 2023.
112. Tanaka T, Narazaki M. Cytokine signaling in inflammation. Nat Rev Immunol. 2021.
113. O'Shea JJ, et al. Cytokines and immune regulation. Nat Rev Immunol. 2022.
114. Pan SY, et al. Herbal medicines and inflammatory cytokine modulation. Nat Rev Drug Discov. 2020.
115. Reuter S, et al. Oxidative stress and inflammation. Free Radic Biol Med. 2020.
116. Hewlings SJ, Kalman DS. Curcumin and antioxidant mechanisms. Foods. 2020.
117. Mao QQ, et al. Antioxidant properties of ginger phytochemicals. Food Chem. 2021.
118. Siddiqui MZ. Antioxidant and anti-inflammatory activity of Boswellia. Indian J Pharm Sci. 2021.
119. Caesar LK, Cech NB. Synergy and antagonism in natural product extracts. Nat Prod Rep. 2020.
120. Li S, Zhang B. Traditional herbal medicine network pharmacology: theory and methodology. Chin J Nat Med. 2021.
121. Pan SY, et al. New perspectives on herbal medicines and polyherbal formulations. Nat Rev Drug Discov. 2020.
122. Wagner H. Synergy research in phytomedicine: pharmacodynamic interactions. Phytomedicine. 2021.
123. Kunnumakkara AB, et al. Curcumin as a regulator of inflammatory pathways. Biomedicines. 2021.
124. Roy NK, et al. Boswellic acids in inflammatory diseases. Biomed Pharmacother. 2021.

125. Efferth T, Koch E. Complex interactions between phytochemicals and biological targets. Planta Med. 2021.
126. Williamson EM. Pharmacokinetic synergy in herbal medicines. Phytother Res. 2020.
127. Atanasov AG, et al. Natural products in drug discovery and pharmacokinetics. Biotechnol Adv. 2021.
128. Hopkins AL. Network pharmacology: paradigm shift in drug discovery. Nat Chem Biol. 2020.
129. Li X, et al. Systems pharmacology approaches to herbal medicine. Trends Pharmacol Sci. 2021.
130. Ulrich-Merzenich G, et al. Combination effects of phytomedicines. Phytomedicine. 2020.
131. Tang J, et al. Network pharmacology-based analysis of herbal medicine synergy. Front Pharmacol. 2022.
132. Zhang R, et al. Metabolomics insights into herbal medicine synergy. Phytochem Rev. 2022.
133. Wang X, et al. Systems biology approaches in polyherbal formulations. Front Pharmacol. 2023.
134. Gupta M, et al. Experimental models for evaluation of anti-inflammatory agents. J Pharmacol Toxicol Methods. 2020.
135. Singh S, et al. Herbal anti-inflammatory agents and their mechanisms. Biomed Pharmacother. 2021.
136. Morris CJ. Carrageenan-induced paw edema model in inflammation research. Methods Mol Biol. 2020.
137. Sharma JN, et al. Mechanisms of carrageenan-induced inflammation. Inflammopharmacology. 2021.
138. Winter CA, et al. Cotton pellet granuloma method for evaluation of anti-inflammatory drugs. Methods Find Exp Clin Pharmacol. 2020.
139. Sosa S, et al. Evaluation of anti-inflammatory activity using granuloma models. J Ethnopharmacol. 2021.
140. Brand DD, et al. Animal models of rheumatoid arthritis. Nat Rev Rheumatol. 2021.
141. Firestein GS, McInnes IB. Immunopathogenesis of rheumatoid arthritis. Immunity. 2020.
142. Eddy NB, Leimbach D. Synthetic analgesics and hot plate method. J Pharmacol Exp Ther. 2020.
143. Le Bars D, et al. Animal models of nociception and analgesia. Pharmacol Rev. 2021.
144. D'Amour FE, Smith DL. Tail flick method for measuring analgesia. J Pharmacol Exp Ther. 2020.
145. Mogil JS. Animal models of pain and analgesia research. Nat Rev Neurosci. 2021.
146. Koster R, et al. Acetic acid-induced writhing test as an analgesic screening method. Eur J Pharmacol. 2020.
147. Collier HOJ, et al. Mechanisms of peripheral analgesic activity. Br J Pharmacol. 2021.
148. Williamson EM. Synergy in phytomedicine and herbal combinations. Phytomedicine. 2020.
149. Ulrich-Merzenich G, et al. Combination effects of phytochemicals in inflammation therapy. Phytother Res. 2021.
150. Atanasov AG, et al. Natural products in anti-inflammatory drug discovery. Biotechnol Adv. 2021.
151. Li S, et al. Systems pharmacology of herbal combinations. Front Pharmacol. 2022.
152. Ekor M. The growing use of herbal medicines and safety concerns. Front Pharmacol. 2021.
153. Fasinu PS, Bouic PJ, Rosenkranz B. Herbal medicine safety and toxicological considerations. Toxicol Rep. 2020.
154. OECD. Guidelines for the Testing of Chemicals: Acute Oral Toxicity. OECD Publishing. 2020.
155. Amalraj A, et al. Safety and toxicity evaluation of curcumin and turmeric extracts. J Tradit Complement Med. 2021.
156. Parasuraman S. Toxicological screening methods for herbal medicines. J Pharmacol Pharmacother. 2020.
157. Choudhary N, Sekhon BS. Toxicological evaluation of herbal medicines. Pharmacogn Rev. 2021.
158. Izzo AA. Interactions between herbal medicines and conventional drugs. Drugs. 2020.
159. Zhou S, et al. Herb–drug interactions involving cytochrome P450 enzymes. Curr Drug Metab. 2021.
160. Fugh-Berman A. Herb–drug interactions: review and clinical implications. Lancet. 2020.
161. Hewlings SJ, Kalman DS. Curcumin safety and clinical applications. Foods. 2020.
162. Lete I, Allué J. Safety profile of ginger in medicinal use. Nutrients. 2021.
163. Sengupta K, et al. Safety evaluation of Boswellia extracts in clinical studies. Phytother Res. 2021.
164. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata safety and pharmacology. Planta Med. 2020.
165. Pan SY, et al. Safety and toxicity considerations of herbal medicines. Nat Rev Drug Discov. 2021.
166. Kunle OF, Egharevba HO, Ahmadu PO. Standardization of herbal medicines—A review. Int J Biodivers Conserv. 2020.
167. Sahoo N, Manchikanti P, Dey S. Herbal drugs: standards and regulation. Fitoterapia. 2021.
168. World Health Organization. WHO guidelines on quality control methods for herbal medicines. WHO Press. 2021.
169. Li S, et al. Chemical variability and quality evaluation of herbal medicines. Chin J Nat Med. 2021.
170. Liang YZ, et al. Chemical fingerprinting of herbal medicines. J Chromatogr B. 2020.
171. Raclariu AC, et al. DNA barcoding for authentication of medicinal plants. Front Pharmacol. 2021.
172. Zhao Z, et al. Quality control of herbal medicines. J Ethnopharmacol. 2022.
173. Fan XH, Cheng YY. Marker compounds in herbal medicine standardization. J Pharm Biomed Anal. 2021.
174. Chemat F, et al. HPLC techniques for phytochemical analysis. TrAC Trends Anal Chem. 2020.
175. Wolfender JL, et al. LC-MS based metabolomics in natural product research. Nat Prod Rep. 2021.
176. Sarker SD, Nahar L. Hyphenated chromatographic techniques for herbal analysis. Phytochem Anal. 2020.
177. Bicchi C, et al. GC-MS analysis of essential oils and plant metabolites. J Chromatogr A. 2021.
178. Kumar A, et al. Analytical techniques for quality control of herbal medicines. Front Pharmacol. 2022.

**International Journal of Pharmacy and Pharmaceutical Research (IJPPR)**
Volume 32, Issue 4, April 2026 **ijppr.humanjournals.com** ISSN: 2349-7203

How to cite this article:
Ishteha Hussain et al. Ijppr.Human, 2026; Vol. 32 (4): 605-624.




| | |
|---|---|
|  | Author Name – Ishteha Hussain<br><br>Author Affiliation- M.pharm.<br><br>Author Address/Institute Address- Advance Institute of Biotech and Paramedical Sciences. |
|  | Author Name-Utkarsh Sharma<br><br>Author Affiliation- Assistant Professor, Department of Pharmacology<br><br>Author Address/Institute Address- Advance Institute of Biotech and Paramedical Sciences. |
| **Image**<br><br>**Author -3** | Author Name- Anurag Singh<br><br>Author Affiliation-Associate Professor, Department of Pharmacology<br><br>Author Address/Institute Address- Advance Institute of Biotech and Paramedical Sciences. |